Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.

Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN.

Nat Commun. 2017 Sep 19;8(1):607. doi: 10.1038/s41467-017-00452-4.

2.

The state of melanoma: challenges and opportunities.

Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA.

Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16. doi: 10.1111/pcmr.12475. Epub 2016 Apr 17.

3.

Antimelanoma CTL recognizes peptides derived from an ORF transcribed from the antisense strand of the 3' untranslated region of TRIT1.

Swoboda RK, Somasundaram R, Caputo-Gross L, Marincola FM, Robbins P, Herlyn M, Herlyn D.

Mol Ther Oncolytics. 2015 Jan 14;1:14009. doi: 10.1038/mto.2014.9. eCollection 2015.

4.

Meeting report from the 10th International Congress of the Society for Melanoma Research, Philadelphia, PA, November 2013.

Vultur A, O'Connell M, Webster M, Villanueva J, Herlyn D, Somasundaram R, Krepler C, Zaidi R, Patton E, Sekulic A, Jonsson G, Weeraratna AT.

Pigment Cell Melanoma Res. 2014 Jul;27(4):E1-E12. doi: 10.1111/pcmr.12240. Epub 2014 May 6. No abstract available.

5.

Highlights of melanoma research presented at the 49th annual meeting of the American Society of Clinical Oncology in Chicago, 2013.

Krepler C, Herlyn D.

Pigment Cell Melanoma Res. 2014 Jan;27(1):E1-5. doi: 10.1111/pcmr.12182. Epub 2013 Nov 1. No abstract available.

PMID:
24118967
6.

Highlights of melanoma research presented at the 48th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, June 1-5, 2012.

Herlyn D, Krepler C.

Cancer Immunol Immunother. 2013 Jun;62(6):1131-5. doi: 10.1007/s00262-013-1399-5. Epub 2013 Apr 16. No abstract available.

PMID:
23589108
7.

Highlights of the 2012 Congress of the Society for Melanoma Research, 8-11 November 2012, Hollywood, CA.

Vultur A, Webster M, Villanueva J, Herlyn D.

Melanoma Res. 2013 Jun;23(3):237-40. doi: 10.1097/CMR.0b013e3283610528.

PMID:
23546222
8.

Highlights of novel melanoma therapies presented at the 8th International Congress of the Society for Melanoma Research (SMR) Tampa, FL, November 9-11, 2011.

Herlyn D.

Cancer Immunol Immunother. 2012 Jun;61(6):949-51. doi: 10.1007/s00262-012-1228-2. Epub 2012 Mar 7. No abstract available.

PMID:
22392191
9.

In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2.

Berencsi K, Rani P, Zhang T, Gross L, Mastrangelo M, Meropol NJ, Herlyn D, Somasundaram R.

J Transl Med. 2011 Mar 30;9:33. doi: 10.1186/1479-5876-9-33.

10.

EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.

Heubner M, Errico D, Kasimir-Bauer S, Herlyn D, Kimmig R, Wimberger P.

Med Oncol. 2011 Jun;28(2):626-30. doi: 10.1007/s12032-010-9486-3. Epub 2010 Apr 10.

PMID:
20383668
11.

Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient.

Swoboda RK, Somasundaram R, Caputo L, Berencsi K, von Franzke P, Taylor DD, Marincola FM, Meropol NJ, Sigurdson E, Miller E, Herlyn D.

Int J Cancer. 2010 Sep 1;127(5):1124-30. doi: 10.1002/ijc.25133.

12.

Chemokines and the microenvironment in neuroectodermal tumor-host interaction.

Somasundaram R, Herlyn D.

Semin Cancer Biol. 2009 Apr;19(2):92-6. doi: 10.1016/j.semcancer.2008.11.002. Epub 2008 Nov 13. Review.

13.

Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.

Zhang T, Herlyn D.

Cancer Immunol Immunother. 2009 Apr;58(4):475-92. doi: 10.1007/s00262-008-0598-y. Epub 2008 Oct 17. Review.

14.

Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.

Wondimu A, Zhang T, Kieber-Emmons T, Gimotty P, Sproesser K, Somasundaram R, Ferrone S, Tsao CY, Herlyn D.

Cancer Immunol Immunother. 2008 Jul;57(7):1079-89.

15.

Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display.

Swoboda RK, Somasundaram R, Caputo L, Ochoa EM, Gimotty PA, Marincola FM, Van Belle P, Barth S, Elder D, Guerry D, Czerniecki B, Schuchter L, Vonderheide RH, Herlyn D.

Cancer Res. 2007 Apr 15;67(8):3555-9.

16.

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, Clifford E, Perkins S, Beitsch P, Khan A, Morrison L, Herlyn D, Terstappen LW, Lane N, Wang J, Uhr J.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17361-5. Epub 2006 Nov 1.

17.

Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-cell migration toward melanoma cells.

Zhang T, Somasundaram R, Berking C, Caputo L, Van Belle P, Elder D, Czerniecki B, Hotz S, Schuchter L, Spitz FR, Berencsi K, Rani P, Marincola F, Qiu R, Herlyn D.

Cancer Biol Ther. 2006 Oct;5(10):1304-12. Epub 2006 Oct 4.

PMID:
16929176
18.

High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model.

Wei Q, Clarke L, Scheidenhelm DK, Qian B, Tong A, Sabha N, Karim Z, Bock NA, Reti R, Swoboda R, Purev E, Lavoie JF, Bajenaru ML, Shannon P, Herlyn D, Kaplan D, Henkelman RM, Gutmann DH, Guha A.

Cancer Res. 2006 Aug 1;66(15):7429-37.

19.

Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture.

Berencsi K, Meropol NJ, Hoffman JP, Sigurdson E, Giles L, Rani P, Somasundaram R, Zhang T, Kalabis J, Caputo L, Furth E, Swoboda R, Marincola F, Herlyn D.

Cancer Immunol Immunother. 2007 Mar;56(3):359-70. Epub 2006 Jun 17.

PMID:
16783574
20.

Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.

Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, van Belle P, Hotz S, Elder DE, Marincola FM, Schuchter L, Guerry D, Czerniecki BJ, Herlyn D.

Cancer Res. 2006 Mar 15;66(6):3287-93.

21.

Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4.

Zhang T, Somasundaram R, Berencsi K, Caputo L, Gimotty P, Rani P, Guerry D, Swoboda R, Herlyn D.

Eur J Immunol. 2006 Feb;36(2):457-67.

22.

CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma.

Somasundaram R, Caputo L, Guerry D, Herlyn D.

J Transl Med. 2005 Nov 10;3:41.

23.

Serum antibodies to EpCAM in healthy donors but not ulcerative colitis patients.

Furth EE, Li J, Purev E, Solomon AC, Rogler G, Mick R, Putt M, Zhang T, Somasundaram R, Swoboda R, Herlyn D.

Cancer Immunol Immunother. 2006 May;55(5):528-37. Epub 2005 Jul 21.

PMID:
16034560
24.

CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture.

Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P, Guerry D, Furth E, Rollins BJ, Putt M, Gimotty P, Swoboda R, Herlyn M, Herlyn D.

J Immunol. 2005 May 1;174(9):5856-63.

25.

Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility.

Gesierich S, Paret C, Hildebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn D, Ashman LK, Zöller M.

Clin Cancer Res. 2005 Apr 15;11(8):2840-52.

26.

Circulating tumor cells in patients with breast cancer dormancy.

Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW.

Clin Cancer Res. 2004 Dec 15;10(24):8152-62.

27.

Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R).

Purev E, Cai D, Miller E, Swoboda R, Mayer T, Klein-Szanto A, Marincola FM, Mick R, Otvos L, Wunner W, Birebent B, Somasundaram R, Wikstrand CJ, Bigner D, DeMichele A, Acs G, Berlin JA, Herlyn D.

J Immunol. 2004 Nov 15;173(10):6472-80.

28.

Colon cancer antigen and anti-idiotype vaccines.

Herlyn D, Birebent B, Akis N, Purev E, Somasundaram R, Mitchell E, Maguire H, Staib L, Mastrangelo M.

Cancer Chemother Biol Response Modif. 2003;21:287-98. No abstract available.

PMID:
15338751
29.

HER-2 gene amplification can be acquired as breast cancer progresses.

Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J.

Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9393-8. Epub 2004 Jun 11.

30.

Detection of HLA class II-dependent T helper antigen using antigen phage display.

Somasundaram R, Satyamoorthy K, Caputo L, Yssel H, Herlyn D.

Clin Exp Immunol. 2004 Feb;135(2):247-52.

31.

Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.

Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC.

Clin Cancer Res. 2003 Oct 15;9(13):4782-91.

32.

[1st successful immunization of pancreas and colorectal carcinoma patients with CO17-1A-vaccine].

Staib L, Braumüller H, Leeser C, Beger HG, Somasundaram R, Li W, Birebent B, Herlyn D.

Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):53-8. German.

PMID:
14518212
33.

Recombinant CD63/ME491/neuroglandular/NKI/C-3 antigen inhibits growth of established tumors in transgenic mice.

Li J, Li W, Liang S, Cai D, Kieny MP, Jacob L, Linnenbach A, Abramczuk JW, Bender H, Sproesser K, Swoboda R, Somasundaram R, Guerry D, Herlyn D.

J Immunol. 2003 Sep 15;171(6):2922-9.

34.

Addition of interleukin-12 to GA733 tumor protein vaccine leads to development of tumor protective immunity despite surgical stress.

Kirman I, Poltoratskaia N, Herlyn D, Whelan RL.

Surg Endosc. 2003 Jul;17(7):1135-9. Epub 2003 Mar 28.

PMID:
12658425
35.

Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside.

Basak S, Birebent B, Purev E, Somasundaram R, Maruyama H, Zaloudik J, Swoboda R, Strittmatter W, Li W, Luckenbach A, Song H, Li J, Sproesser K, Guerry D, Nair S, Furukawa K, Herlyn D.

Cancer Immunol Immunother. 2003 Mar;52(3):145-54. Epub 2003 Feb 11.

PMID:
12649743
36.

Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients.

Birebent B, Mitchell E, Akis N, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nair S, Cai D, Zhang T, Herlyn DM.

Vaccine. 2003 Apr 2;21(15):1601-12.

PMID:
12639481
37.

A CD4+, HLA-DR7-restricted T-helper lymphocyte clone recognizes an antigen shared by human malignant melanoma and glioma.

Somasundaram R, Swoboda R, Caputo L, Lee A, Jackson N, Marincola FM, Guerry D, Herlyn D.

Int J Cancer. 2003 Apr 10;104(3):362-8.

38.

Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta.

Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, Birebent B, Bloome E, Kim J, Berencsi K, Mastrangelo M, Herlyn D.

Cancer Res. 2002 Sep 15;62(18):5267-72.

39.

Immunization procedures for anti-idiotypic antibody induction in mice and rats.

Maruyama H, Sperlagh M, Zaloudik J, Liang S, Mizuki K, Molthoff C, Herlyn D.

J Immunol Methods. 2002 Jun 1;264(1-2):121-33.

PMID:
12191516
40.

Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice.

Zaloudik J, Li W, Jacob L, Kieny MP, Somasundaram R, Acres B, Song H, Zhang T, Li J, Herlyn D.

Cancer Gene Ther. 2002 Apr;9(4):382-9.

41.

Anti-idiotypic antibody (ab2) vaccines: coupling of Ab2 BR3E4 to KLH increases humoral and/or cellular immune responses in animals and colorectal cancer patients.

Birebent B, Koido T, Mitchell E, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nair S, Cai E, Herlyn D.

J Cancer Res Clin Oncol. 2001 Oct;127 Suppl 2:R27-33.

PMID:
11768621
42.

Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth.

BenAmmar-Ceccoli S, Humblot S, Crouzier R, Acres B, Kieny MP, Herlyn D, Pasquali JL, Martin T.

Cancer Gene Ther. 2001 Oct;8(10):815-26.

43.

Anti-idiotypic antibody and recombinant antigen vaccines in colorectal cancer patients.

Birebent B, Somasundaram R, Purev E, Li W, Mitchell E, Hoey D, Bloom E, Mastrangelo M, Maguire H, Harris DT, Staib L, Braumuller H, Leeser C, Kuttner N, Beger HG, Herlyn D.

Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):107-13.

PMID:
11418307
44.

Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients.

Staib L, Birebent B, Somasundaram R, Purev E, Braumüller H, Leeser C, Küttner N, Li W, Zhu D, Diao J, Wunner W, Speicher D, Beger HG, Song H, Herlyn D.

Int J Cancer. 2001 Apr 1;92(1):79-87.

45.

Isolation of the melanoma-associated antigen p23 using antibody phage display.

Li J, Pereira S, Van Belle P, Tsui P, Elder D, Speicher D, Deen K, Linnenbach A, Somasundaram R, Swoboda R, Herlyn D.

J Immunol. 2001 Jan 1;166(1):432-8.

46.

Oligomeric state of the colon carcinoma-associated glycoprotein GA733-2 (Ep-CAM/EGP40) and its role in GA733-mediated homotypic cell-cell adhesion.

Trebak M, Begg GE, Chong JM, Kanazireva EV, Herlyn D, Speicher DW.

J Biol Chem. 2001 Jan 19;276(3):2299-309. Epub 2000 Oct 31.

47.

Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector.

Basak S, Eck S, Gutzmer R, Smith AJ, Birebent B, Purev E, Staib L, Somasundaram R, Zaloudik J, Li W, Jacob L, Mitchell E, Speicher D, Herlyn D.

Ann N Y Acad Sci. 2000 Jun;910:237-52; discussion 252-3.

PMID:
10911917
48.

Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine.

Maruyama H, Zaloudik J, Li W, Sperlagh M, Koido T, Somasundaram R, Scheck S, Prewett M, Herlyn D.

Cancer Immunol Immunother. 2000 Jun;49(3):123-32.

PMID:
10881691
49.

Recognition of human colon cancer by T cells transduced with a chimeric receptor gene.

Daly T, Royal RE, Kershaw MH, Treisman J, Wang G, Li W, Herlyn D, Eshhar Z, Hwu P.

Cancer Gene Ther. 2000 Feb;7(2):284-91.

50.

CD4(+), HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells.

Somasundaram R, Robbins P, Moonka D, Loh E, Marincola F, Patel A, Guerry D, Herlyn D.

Int J Cancer. 2000 Jan 15;85(2):253-9.

Supplemental Content

Loading ...
Support Center